Q2 2021 BUSINESS UPDATE

AUG 12, 2021

COPYRIGHT © ABCELLERA

DISCLAIMER

This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

COPYRIGHT © ABCELLERA



STRONG GROWTH OF CORE BUSINESS

19
NEW programs under contract

6
NEW programs started

3
MOLECULES entered clinical testing

138
cumulative programs under contract

$792.6M
in cash & cash equivalents

$65M
in accounts receivable (AR) + accrued AR

Q2 2021.
BUSINESS UPDATE SUMMARY.

2 ANTIBODIES FOR COVID-19



There is an increase in the number of COVID-19 cases globally, with over 100,000 daily cases reported in the US alone.

bamlanivimab + etesevimab

US shipments of bamlanivimab together with etesevimab halted in June because of the prevalence of resistant variants at the time (Gamma and Beta).

Effective against **Delta variant***

bebtelovimab

Currently in Phase 2 clinical trials alone and in combination with bamlanivimab and etesevimab.

Effective against **variants** of concern, including the **Delta variant***

* Shown to be effective against the Delta variant in preclinical studies

COPYRIGHT © ABCELLERA

DIVERSE PORTFOLIO THAT ALREADY COVERS MOST THERAPEUTIC AREAS

138 **PROGRAMS UNDER CONTRACT**



oncology / neuro-degeneration / pain

allergic inflammation / ophthalmology / infectious disease

autoimmune diseases / women's health / genitourinary system / cardiovascular

COPYRIGHT © ABCELLERA

UNLOCK NEW TARGETS

Our partners look to us to unlock new targets across a range of target types. For targets that have been selected by our partners, a third include challenging, high-value targets:

28%

DIFFICULT targets

72%

STANDARD targets



multi-pass transmembrane targets



high homology targets



peptide-MHC targets

COPYRIGHT © ABCELLERA

EMPOWER NEW MODALITIES FOR NEXT-GEN THERAPIES

Our platform is an operating system designed to support many next-gen modalities, including:



IgGs, IgMs, IgAs



bispecific antibodies



single chains (scFvs)



radioisotope conjugates



CAR-T Cell therapies



CNS-delivered antibodies

COPYRIGHT © ABCELLERA

115 PUCS
WITH DOWNSTREAM PARTICIPATION

Our Programs Under Contract with downstream participation span the entire spectrum of drug development firms:



COPYRIGHT © ABCELLERA

FORWARD INTEGRATION TO ACCELERATE DRUG DEVELOPMENT

ABCELLERA DEVELOPMENT × **PARTNER DEVELOPMENT** = **COMMERCIAL SALE**

Phase 1 → **Phase 2** → **Phase 3 & Approval**

Antibody Discovery

TECH STACK

Preclinical

Expansion into GMP / CMC manufacturing:



COPYRIGHT © ABCELLERA

CREATE & CAPTURE VALUE WITH **DEEPER POSITIONS**

Diverse deal structures provide the opportunity to deepen our position in successful molecules:



COPYRIGHT © ABCELLERA

CENTRALIZE INNOVATION TO MAKE
DRUG DISCOVERY FASTER, MORE EFFICIENT & MORE COST EFFECTIVE.



COPYRIGHT © ABCELLERA

Q2 2021

FINANCIALS UPDATE

COPYRIGHT © ABCELLERA

Partnership business growth shows great strength in 1H 2021.

of
Discovery Partners



Cumulative # of
Programs Under Contract



Cumulative # of
Program Starts



– **WITHOUT** downstream participation
+ **WITH** downstream participation

Note: Showing year-end figures except for most recent quarter.
Historical results are not necessarily indicative of future results.

COPYRIGHT © ABCELLERA

Four molecules in the clinic, over a dozen in preclinical development.

MOLECULE	STAGE	PARTNER	THERAPEUTIC AREA	PROGRAM TYPE
bamlanivimab (LY-CoV555)	Marketed, Emergency Use Authorization (EUA)	Lilly	• COVID-19	AbCellera Discovery Partnership
bebetelovimab (LY-CoV1404)	Phase II	Lilly	• COVID-19	
NBL-012	Phase I	NovaRock Biotherapeutics	• dermatology • gastrointestinal disease • immunology	Trianni License
NBL-015	IND approved	NovaRock Biotherapeutics	• oncology	

COPYRIGHT © ABCELLERA

$27.6M revenue driven by COVID-19 program.



COPYRIGHT © ABCELLERA

Operating expenses reflect continued strengthening of the platform.

Operating Expenses USD

RESEARCH & DEVELOPMENT



SALES & MARKETING



GENERAL & ADMIN



COPYRIGHT © ABCELLERA

Net loss of $2.3M: Equivalent to ($0.01) per share (basic & diluted).

Earnings / Loss USD

NET EARNINGS (LOSS)



EARNINGS (LOSS) PER SHARE: BASIC & DILUTED



COPYRIGHT © ABCELLERA

Operations results financed investments in H1 and further strengthened liquidity.



COPYRIGHT © ABCELLERA

THANK YOU



COPYRIGHT © ABCELLERA